Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Treatment of cancer cells with anticancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumor's gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA peptides on the surface of the tumor cells and be developed into anticancer immunotherapeutics. For example, the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine (Decitabine) has limited antitumor efficacy, yet it induces the expression of many genes, including CTAs that are normally silenced in the healthy adult tissues. In this study, the presentation of many new HLA peptides derived from CTAs and induced by Decitabine was demonstrated in three human Glioblastoma cell lines. Such presentation of CTA-derived HLA peptides can be exploited for development of new treatment modalities, combining drug treatment with anti-CTA targeted immunotherapy. The Decitabine-induced HLA peptidomes include many CTAs that are not normally detected in healthy tissues or in cancer cells, unless treated with the drug. In addition, the study included large-scale analyses of the simultaneous effects of Decitabine on the transcriptomes, proteomes and HLA peptidomes of the human Glioblastoma cells. It demonstrates the poor correlations between these three levels of gene expression, both in their total levels and in their response to the drug. The proteomics and HLA peptidomics data are available via ProteomeXchange with identifier PXD003790 and the transcriptomics data are available via GEO with identifier GSE80137.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“The iBAQ intensities (69) of the proteomes were defined by the MaxQuant software (52).”
MethodCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Although neo-antigens are likely the preferred type of immunotherapeutics (11, 13, 14, 22, 65) they are rare, difficult to identify and will require costly analyses and validations before their routine incorporation into the personalized immunotherapy pipeline.”
BackgroundCellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729
Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., Kondo, Y., Sekido, Y., Kawatsura, H., Narita, Y., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23407 · Cited by 93
Research works printed but not linked: 69
- Alifieris, 2015, Glioblastoma multiforme: Pathogenesis and treatment, Pharmacol. Ther, 152, 63, 10.1016/j.pharmthera.2015.05.005 · DOI · Paper page
- Mohme, 2014, Immunological challenges for peptide-based immunotherapy in glioblastoma, Cancer Treat. Rev, 40, 248, 10.1016/j.ctrv.2013.08.008 · DOI
- Weiss, 2015, Immunotherapy for glioblastoma: concepts and challenges, Curr. Opin. Neurol, 28, 639, 10.1097/WCO.0000000000000249 · DOI
- Galluzzi, 2014, Classification of current anticancer immunotherapies, Oncotarget, 5, 12472, 10.18632/oncotarget.2998 · DOI · Paper page
- Rammensee, 2013, HLA ligandome tumor antigen discovery for personalized vaccine approach, Expert Rev. Vaccines, 12, 1211, 10.1586/14760584.2013.836911 · DOI
- Pol, 2015, Trial Watch: Peptide-based anticancer vaccines, Oncoimmunology, 4, e974411, 10.4161/2162402X.2014.974411 · DOI · Paper page
- Comber, 2014, MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines, Therap. Adv. Vaccines, 2, 77, 10.1177/2051013614525375 · DOI · Paper page
- de Verteuil, 2012, Origin and plasticity of MHC I-associated self peptides, Autoimmunity Rev, 11, 627, 10.1016/j.autrev.2011.11.003 · DOI
- Granados, 2014, The nature of self for T cells-a systems-level perspective, Curr. Opin. Immunol, 34C, 1
- Heemskerk, 2013, The cancer antigenome, EMBO J, 32, 194, 10.1038/emboj.2012.333 · DOI · Paper page
- Cohen, 2015, Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes, J. Clin. Invest, 125, 3981, 10.1172/JCI82416 · DOI · Paper page
- Gubin, 2015, Tumor neoantigens: building a framework for personalized cancer immunotherapy, J. Clin. Invest, 125, 3413, 10.1172/JCI80008 · DOI · Paper page
- Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 · DOI · Paper page
- Peper, 2015, A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy, Cancer Immunol. Immunother, 64, 1295, 10.1007/s00262-015-1682-8 · DOI
- Ilyas, 2015, Landscape of Tumor Antigens in T Cell Immunotherapy, J. Immunol, 195, 5117, 10.4049/jimmunol.1501657 · DOI · Paper page
- Hinrichs, 2013, Reassessing target antigens for adoptive T-cell therapy, Nat. Biotechnol, 31, 999, 10.1038/nbt.2725 · DOI · Paper page
- Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc. Natl. Acad. Sci. U.S.A, 94, 1914, 10.1073/pnas.94.5.1914 · DOI · Paper page
- Whitehurst, 2014, Cause and consequence of cancer/testis antigen activation in cancer, Annu. Rev. Pharmacol. Toxicol, 54, 251, 10.1146/annurev-pharmtox-011112-140326 · DOI · Paper page
- Cheng, 2011, Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis, Spermatogenesis, 1, 209, 10.4161/spmg.1.3.17990 · DOI
- Gjerstorff, 2015, Oncogenic cancer/testis antigens: prime candidates for immunotherapy, Oncotarget, 6, 15772, 10.18632/oncotarget.4694 · DOI · Paper page
- Weber, 1994, Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine, Cancer Res, 54, 1766
- De Smet, 1996, The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc. Natl. Acad. Sci. U.S.A, 93, 7149, 10.1073/pnas.93.14.7149 · DOI · Paper page
- Fratta, 2011, The biology of cancer testis antigens: putative function, regulation and therapeutic potential, Mol. Oncol, 5, 164, 10.1016/j.molonc.2011.02.001 · DOI · Paper page
- Feinberg, 1983, Hypomethylation distinguishes genes of some human cancers from their normal counterparts, Nature, 301, 89, 10.1038/301089a0 · DOI · Paper page
- Gama-Sosa, 1983, The 5-methylcytosine content of DNA from human tumors, Nucleic Acids Res, 11, 6883, 10.1093/nar/11.19.6883 · DOI · Paper page
- Heninger, 2015, Augmenting antitumor immune responses with epigenetic modifying agents, Front. Immunol, 6, 1
- Valdespino, 2015, (Potential of epigenetic therapies in the management of solid tumors, Cancer Manag. Res, 7, 241, 10.2147/CMAR.S70358 · DOI
- Claus, 2005, Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents, Semin. Oncol, 32, 511, 10.1053/j.seminoncol.2005.07.024 · DOI
- Everson, 2016, Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma, Neuro. Oncol, 18, 368, 10.1093/neuonc/nov153 · DOI
- Serrano, 2001, Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment, Int. J. Cancer, 94, 243, 10.1002/ijc.1452 · DOI · Paper page
- Coral, 1999, Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR), J. Immunother, 22, 16, 10.1097/00002371-199901000-00003 · DOI · Paper page
- Nie, 2001, DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas, Carcinogenesis, 22, 1615, 10.1093/carcin/22.10.1615 · DOI · Paper page
- Coral, 2012, Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications, Br. J. Cancer, 107, 1116, 10.1038/bjc.2012.361 · DOI
- Konkankit, 2011, Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway, J. Transl. Med, 9, 192, 10.1186/1479-5876-9-192 · DOI · Paper page
- Weiser, 2001, Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1, J. Immunother, 24, 151, 10.1097/00002371-200103000-00010 · DOI · Paper page
- Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell. Proteomics, 14, 3105, 10.1074/mcp.O115.052431 · DOI · Paper page
- Fortier, 2008, The MHC class I peptide repertoire is molded by the transcriptome, J. Exp. Med, 205, 595, 10.1084/jem.20071985 · DOI · Paper page
- de Verteuil, 2010, Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules, Mol. Cell. Proteomics, 9, 2034, 10.1074/mcp.M900566-MCP200 · DOI · Paper page
- Granados, 2012, MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements, Blood, 119, e181, 10.1182/blood-2012-02-412593 · DOI
- Weinzierl, 2007, Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface, Mol. Cell. Proteomics, 6, 102, 10.1074/mcp.M600310-MCP200 · DOI · Paper page
- Hoof, 2012, Proteome sampling by the HLA class I antigen processing pathway, PLoS Comput. Biol, 8, e1002517, 10.1371/journal.pcbi.1002517 · DOI
- Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell. Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
- Milner, 2013, The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome, Mol. Cell. Proteomics, 12, 1853, 10.1074/mcp.M112.026013 · DOI
- Ishihama, 2006, Modular stop and go extraction tips with stacked disks for parallel and multidimensional Peptide fractionation in proteomics, J. Proteome Res, 5, 988, 10.1021/pr050385q · DOI · Paper page
- Bourdetsky, 2014, The nature and extent of contributions by defective ribosome products to the HLA peptidome, Proc. Natl. Acad. Sci. U.S.A, 111, E1591, 10.1073/pnas.1321902111 · DOI
- Cox, 2008, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification, Nat. Biotechnol, 26, 1367, 10.1038/nbt.1511 · DOI · Paper page
- Cox, 2011, Andromeda: a peptide search engine integrated into the MaxQuant environment, J. Proteome Res, 10, 1794, 10.1021/pr101065j · DOI · Paper page
- Vizcaino, 2016, 2016 update of the PRIDE database and its related tools, Nucleic Acids Res, 44, D447, 10.1093/nar/gkv1145 · DOI · Paper page
- Trapnell, 2009, TopHat: discovering splice junctions with RNA-Seq, Bioinformatics, 25, 1105, 10.1093/bioinformatics/btp120 · DOI · Paper page
- Anders, 2015, HTSeq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, 166, 10.1093/bioinformatics/btu638 · DOI · Paper page
- Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res, 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
- Andreatta, 2016, Gapped sequence alignment using artificial neural networks: application to the MHC class I system, Bioinformatics, 32, 511, 10.1093/bioinformatics/btv639 · DOI · Paper page
- Liu, 2016, The interdependence of transcript and protein abundance: new data-new complexities, Mol. Syst. Biol, 12, 856, 10.15252/msb.20156720 · DOI · Paper page
- Wu, 2016, BioGPS: building your own mash-up of gene annotations and expression profiles, Nucleic Acids Res, 44, D313, 10.1093/nar/gkv1104 · DOI · Paper page
- Wu, 2009, BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources, Genome Biol, 10, R130, 10.1186/gb-2009-10-11-r130 · DOI · Paper page
- Dutoit, 2002, Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting, J. Clin. Invest, 110, 1813, 10.1172/JCI16428 · DOI
- Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int. J. Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S · DOI · Paper page
- Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med, 4, 321, 10.1038/nm0398-321 · DOI · Paper page
- Kalaora, 2016, Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens, Oncotarget, 7, 5110, 10.18632/oncotarget.6960 · DOI · Paper page
- Kanaseki, 2013, ERAAP and tapasin independently edit the amino and carboxyl termini of MHC class I peptides, J. Immunol, 191, 1547, 10.4049/jimmunol.1301043 · DOI
- Rist, 2013, HLA peptide length preferences control CD8+ T cell responses, J. Immunol, 191, 561, 10.4049/jimmunol.1300292 · DOI
- Li, 2015, Gene expression. Statistics requantitates the central dogma, Science, 347, 1066, 10.1126/science.aaa8332 · DOI · Paper page
- Wang, 2014, Leveraging the complementary nature of RNA-Seq and shotgun proteomics data, Proteomics, 14, 2676, 10.1002/pmic.201400184 · DOI
- Lange, 2008, Selected reaction monitoring for quantitative proteomics: a tutorial, Mol. Syst. Biol, 4, 222, 10.1038/msb.2008.61 · DOI · Paper page
- Lesur, 2015, Advances in high-resolution accurate mass spectrometry application to targeted proteomics, Proteomics, 15, 880, 10.1002/pmic.201400450 · DOI
- Admon, 2011, The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing, Mol. Cell. Proteomics, 10, 10.1074/mcp.O111.011833 · DOI
- Granados, 2014, Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides, Nat. Commun, 5, 3600, 10.1038/ncomms4600 · DOI
- Lundegaard, 2012, Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?, Expert Rev. Vaccines, 11, 43, 10.1586/erv.11.160 · DOI
- Yeung, 2013, LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma, Clin. Cancer Res, 19, 1816, 10.1158/1078-0432.CCR-12-2861 · DOI
Cited by
O’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.010 · Cited by 440
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285
Identification of tumor antigens with immunopeptidomics
Chong, C., Coukos, G., & Bassani-Sternberg, M. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01038-8 · Cited by 232
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
“In addition, anticancer drugs can also have marked effects on the immunopeptidome of tumor cells, including HLA surface expression (135), HLA allotype distribution (136), the presentation of vaccine target peptides, as well as the induction of novel, cryptic, treatment-associated ligands (136, 137).”
BackgroundPredicting Antigen Presentation—What Could We Learn From a Million Peptides?
Gfeller, D., & Bassani-Sternberg, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01716 · Cited by 170
Metadata
- Authors
- Shraibman, B., Kadosh, D. M., Barnea, E., & Admon, A.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 15
- Issue
- 9
- Pages
- 3058-3070
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2464113003
- Cited by
- 71
- References
- 7
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1471 d)
- Funders
- Seventh Framework Programme (GAPVAC)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.